Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other research analysts have also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Eupraxia Pharmaceuticals in a report on Wednesday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, October 8th. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, October 29th. Finally, Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Eupraxia Pharmaceuticals has an average rating of “Buy” and an average price target of $11.67.

Eupraxia Pharmaceuticals Stock Down 2.0%

Eupraxia Pharmaceuticals stock opened at $6.27 on Friday. The company has a fifty day simple moving average of $5.99 and a 200-day simple moving average of $5.43. The firm has a market capitalization of $225.48 million, a price-to-earnings ratio of -7.21 and a beta of 1.38. Eupraxia Pharmaceuticals has a 52-week low of $2.68 and a 52-week high of $7.19.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.19) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.04. On average, research analysts anticipate that Eupraxia Pharmaceuticals will post -0.67 EPS for the current fiscal year.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Alyeska Investment Group L.P. purchased a new position in Eupraxia Pharmaceuticals during the 3rd quarter worth $1,475,000. Vivo Capital LLC purchased a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $7,965,000. Velan Capital Investment Management LP acquired a new position in Eupraxia Pharmaceuticals during the third quarter worth about $2,077,000. Integrated Wealth Concepts LLC purchased a new position in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $71,000. Finally, Bank of America Corp DE grew its holdings in Eupraxia Pharmaceuticals by 262.9% during the 3rd quarter. Bank of America Corp DE now owns 45,577 shares of the company’s stock valued at $269,000 after buying an additional 33,018 shares during the last quarter.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.